The Fallacy of Size

Are the world’s largest companies actually your safest investments?Market cap is a lagging indicator of past success, not a real-time shield against structural shifts. From the tech sector to global biopharma, extreme customer concentration and rigid supply chains are creating hidden systemic risks.In my latest analysis, I break down Michael Burry’s high-profile short position on Nvidia and explore the striking parallels playing out in the global pharmaceutical landscape. Listen in!KEY DATA SOURCES — All VerifiedNvidia 10-Q (Q1 FY2027, filed April 2026): Three customers = 30%, 18%, 16% of accounts receivable (64% total). Source: SEC EDGAR.Nvidia CFO Commentary Q4 FY2026: Supply-related commitments of $95.2 billion. Source: SEC EDGAR investor.nvidia.com.Nvidia CFO Commentary Q1 FY2027: Supply commitments grown to $119 billion. Source: SEC EDGAR.Nvidia Q1 FY2026 Press Release (May 2025): $4.5 billion H20 inventory/purchase obligation charge. Source: investor.nvidia.com.Merck 2024 Annual Report: Keytruda revenue $29.5 billion, representing ~46-56% of pharmaceutical sales.Merck SEC risk disclosures: US Keytruda exclusivity expected to end December 2028; IRA pricing begins January 2028.Semaglutide patent expiry India: March 20, 2026. Source: Indian Patent Office records; confirmed by GeneOnline, The Indian Practitioner (March 2026).GLP-1 India market size: ~₹1,446 crore (12 months to February 2026). Source: Pharmarack / Business Line.Global biosimilar patent cliff $100B+ by 2030: DeepCeutix Strategic Briefing, February 2026.Scion Asset Management 13F (Q3 2025, filed November 2025): Put options on 1 million Nvidia shares (~$187M notional). Source: SEC EDGAR. Note: Scion deregistered November 2025. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com